Biotech giant Amgen (NASDAQ:AMGN) announced in a press release Saturday that its PAVES phase 3 trial to evaluate colorectal cancer patients taking the white blood cell-boosting drug Neulasta met its primary endpoint.
In the trial, Neulasta significantly reduced the incidence of febrile neutropenia, which is low white blood cell count combined with fever. The drug more than halved the percent of chemotherapy patients contracting grade 3 or 4 febrile neutropenia as compared to a placebo group, the company said, cutting the incidence from 5.7% to 2.4%.
Amgen Executive Vice President of Research and Development Dr. Sean E. Harper was quoted in the press release as saying, "In addition to providing new data on Neulasta, we believe PAVES will provide valuable information to the oncology community on commonly used chemotherapy regimens."
The company will provide further details on other trial endpoints, such as overall survival and response rate, later. Neulasta was first approved by the FDA back in 2002, with Amgen continuing to provide more data on its blockbuster drug through follow-up trials. Neulasta sold more than $4 billion around the world for the full year 2012, with sales growing 4%.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Will 2018 Be Amgen Inc.'s Best Year Yet?
It would take jumping some really high hurdles.
5 Things Amgen's CEO Just Said That Investors Need to Know
Bob Bradway focused on acquisitions, growth, and more at the J.P. Morgan Healthcare Conference.
2 Top Dividend Stocks to Buy in 2018
If you're looking for rock solid dividends, AbbVie and Amgen should be on your radar this year.